Abstract
AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
Original language | English (US) |
---|---|
Journal | Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery |
Volume | 33 |
Issue number | 1 Suppl |
DOIs | |
State | Published - Mar 2013 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)